Location History:
- Gaithersburg, MD (US) (2022)
- Frederick, MD (US) (2013 - 2023)
Company Filing History:
2 out of 8 
1 out of 3,539 
1 out of 8 Years Active: 2013-2025
Title: Bo Chen: Innovator in FcγRIIA-Binding Molecules
Introduction
Bo Chen is a prominent inventor based in Frederick, MD (US). He has made significant contributions to the field of biomedical research, particularly in the development of binding molecules that target FcγRIIA. With a total of 4 patents to his name, Chen's work has the potential to impact the treatment of various inflammatory and autoimmune diseases.
Latest Patents
Chen's latest patents include innovative FcγRIIA-binding molecules. These molecules, such as humanized monoclonal antibodies, are designed to inhibit FcγRIIA activity. The methods of using these binding molecules aim to treat or prevent inflammatory, immune-mediated, or autoimmune diseases or disorders. His research provides valuable insights into therapeutic applications that could improve patient outcomes.
Career Highlights
Throughout his career, Bo Chen has worked with notable organizations, including Viela Bio, Inc. and the National Institutes of Health, a component of the US Department of Health & Human Services. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Chen's notable coworkers include Katherine Ann Vousden and Gary Patrick Sims. Their collaborative efforts have further advanced the research and development of FcγRIIA-binding molecules.
Conclusion
Bo Chen's innovative work in the field of binding molecules specific for FcγRIIA showcases his dedication to advancing medical science. His contributions have the potential to lead to significant advancements in the treatment of autoimmune diseases.